The DKD rat model established by streptozotocin (STZ) injection and high-fat diet (HFD) and in vitro podocyte experiments proved that AS-IV can alleviate renal pathological changes and renal function decline by regulating IRE-1α/NF-κB/NLRP3 pathway, reduce ERS and inflammation, and improve podocyte pyroptosis to play a protective role [57]. This evidence concerns the gene NLRP3 and diabetic kidney disease.